Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03099109 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 209
- Enrollment target
NCT03099109 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 209 participants.
The verdict
NCT03099109, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 209 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with LY3300054, an anti-programmed death ligand 1 (PD-L1) antibody, in participants with advanced relapsed/refractory solid tumors.
Interventions
- DRUG LY3300054
- DRUG LY3321367
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2017-04-12 |
| Est. Completion | 2023-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03099109
The ClinicalTrials.gov registry entry for NCT03099109 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LY3300054 is the first listed.
NCT03099109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03099109 about?
NCT03099109 is a clinical study titled "A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors". The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with LY3300054, an anti-programmed death ligand 1 (PD-L1) antibody, in participa...
What is the current status of trial NCT03099109?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 209 participants. The study started on 2017-04-12. Estimated completion is 2023-08-30.
What interventions are being tested in trial NCT03099109?
The interventions under investigation include: LY3300054 (DRUG), LY3321367 (DRUG).
Who is sponsoring clinical trial NCT03099109?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.